Trial T0834 was a phase 3, randomized, double-blind, multicenter, placebo-controlled trial designed to evaluate the efficacy of a single oral dose of XOFLUZA compared with placebo in the prevention of influenza in subjects who were household contacts of influenza-infected patients in Japan. Influenza-infected index patients were required to have onset of symptoms for ≤48 hours, and subjects (household contacts) were required to have lived with the influenza-infected index patient for ≥48 hours. A total of 715 subjects (XOFLUZA n=360, placebo n=355) aged 5 years and older were randomized and received a single oral dose of XOFLUZA according to body weight and age, or placebo, on Day 1. Subjects received a single dose of 40 mg or 80 mg of XOFLUZA according to body weight (20 kg to <80 kg or ≥80 kg, respectively). The primary efficacy endpoint was the proportion of household subjects who were infected with influenza virus and presented with fever and at least one respiratory symptom from Day 1 to Day 10. Influenza infection was confirmed by RT-PCR, fever was defined as a body temperature (axillary) ≥37.5°C, and respiratory symptoms were defined as having a symptom of “cough” or “nasal discharge/nasal congestion” with a severity of moderate or severe as assessed by the subject. In subjects that were 5 years of age and older, there was a statistically significant reduction in the proportion of household contacts (subjects) with laboratory-confirmed clinical influenza from 13% (n=47) in the placebo group to 2% (n=6) in the XOFLUZA group.1
RT-PCR = reverse transcription polymerase chain reaction.
Sample a full course of flu treatment with single-dose XOFLUZA.1
Keep it simple with a full course of treatment in a single dose.1
Most people who get the flu recover in 3 to 14 days, but this isn't the case for all patient types.12
XOFLUZA. Prescribing information. Genentech USA, Inc.
XOFLUZA. Prescribing information. Genentech USA, Inc.
Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700-705. doi:10.1097/INF.0000000000002747
Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700-705. doi:10.1097/INF.0000000000002747
TAMIFLU. Prescribing information. Genentech USA, Inc.; 2019.
TAMIFLU. Prescribing information. Genentech USA, Inc.; 2019.
Hayden FG, Sugaya N, Hirotsu N, et al; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923.
Hayden FG, Sugaya N, Hirotsu N, et al; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923.
Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204-1214. doi:10.1016/S1473-3099(20)30004-9
Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204-1214. doi:10.1016/S1473-3099(20)30004-9
Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10)(suppl):1-63. doi:10.1016/S1473-3099(20)30004-9
Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10)(suppl):1-63. doi:10.1016/S1473-3099(20)30004-9
People at higher risk of flu complications. Centers for Disease Control and Prevention (CDC). Accessed July 31, 2024. https://www.cdc.gov/flu/highrisk/index.htm
People at higher risk of flu complications. Centers for Disease Control and Prevention (CDC). Accessed July 31, 2024. https://www.cdc.gov/flu/highrisk/index.htm
National Diabetes Statistics Report. CDC. Accessed August 6, 2024. https://www.cdc.gov/diabetes/php/data-research/index.html
National Diabetes Statistics Report. CDC. Accessed August 6, 2024. https://www.cdc.gov/diabetes/php/data-research/index.html
Most recent national asthma data. CDC. Accessed August 6, 2024. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
Most recent national asthma data. CDC. Accessed August 6, 2024. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
About COPD. CDC. Accessed August 8, 2024. https://www.cdc.gov/copd/about/index.html
About COPD. CDC. Accessed August 8, 2024. https://www.cdc.gov/copd/about/index.html
Heart disease. CDC. Accessed August 6, 2024. https://www.cdc.gov/nchs/fastats/heart-disease.htm
Heart disease. CDC. Accessed August 6, 2024. https://www.cdc.gov/nchs/fastats/heart-disease.htm
Clinical signs and symptoms of influenza. CDC. Accessed July 31, 2024. https://www.cdc.gov/flu/professionals/acip/clinical.htm
Clinical signs and symptoms of influenza. CDC. Accessed July 31, 2024. https://www.cdc.gov/flu/professionals/acip/clinical.htm
Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309-320. doi:10.1056/NEJMoa1915341
Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309-320. doi:10.1056/NEJMoa1915341
2023-2024 U.S. flu season: Preliminary in-season burden estimates. CDC. Accessed July 24, 2024. https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm
2023-2024 U.S. flu season: Preliminary in-season burden estimates. CDC. Accessed July 24, 2024. https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm
Weekly flu vaccination dashboard. CDC. Accessed July 31, 2024. https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-dashboard.html
Weekly flu vaccination dashboard. CDC. Accessed July 31, 2024. https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-dashboard.html
Symptoms of COVID-19. CDC. Updated June 25, 2024. Accessed August 7, 2024. https://www.cdc.gov/covid/signs-symptoms/
Symptoms of COVID-19. CDC. Updated June 25, 2024. Accessed August 7, 2024. https://www.cdc.gov/covid/signs-symptoms/
Allan GM, Arroll B. Prevention and treatment of the common cold: making sense of the evidence. CMAJ. 2014;186(3):190-199. doi:10.1503/cmaj.121442
Allan GM, Arroll B. Prevention and treatment of the common cold: making sense of the evidence. CMAJ. 2014;186(3):190-199. doi:10.1503/cmaj.121442
Cold versus flu. CDC. Accessed August 7, 2024. https://www.cdc.gov/flu/symptoms/coldflu.htm
Cold versus flu. CDC. Accessed August 7, 2024. https://www.cdc.gov/flu/symptoms/coldflu.htm
Is it flu, COVID-19, allergies or a cold? National Institutes of Health. https://newsinhealth.nih.gov/2022/01/it-flu-covid-19-allergies-or-cold. Accessed August 7, 2024.
Is it flu, COVID-19, allergies or a cold? National Institutes of Health. https://newsinhealth.nih.gov/2022/01/it-flu-covid-19-allergies-or-cold. Accessed August 7, 2024.
About adenovirus. Symptoms. CDC. https://www.cdc.gov/adenovirus/about/index.html. Accessed August 7, 2024.
About adenovirus. Symptoms. CDC. https://www.cdc.gov/adenovirus/about/index.html. Accessed August 7, 2024.
Is it a cold, the flu, or COVID-19? National Institute on Aging. https://www.nia.nih.gov/health/covid-19/it-cold-flu-or-covid-19. Accessed August 7, 2024.
Is it a cold, the flu, or COVID-19? National Institute on Aging. https://www.nia.nih.gov/health/covid-19/it-cold-flu-or-covid-19. Accessed August 7, 2024.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Updated April 20, 2023. Accessed July 24, 2024. https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Updated April 20, 2023. Accessed July 24, 2024. https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf
Influenza antiviral medications: summary for clinicians. CDC. Accessed July 24, 2024. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#Table1
Influenza antiviral medications: summary for clinicians. CDC. Accessed July 24, 2024. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#Table1
Samji T. Influenza A: understanding the viral life cycle. Yale J Biol Med. 2009;82(4):153-159.
Samji T. Influenza A: understanding the viral life cycle. Yale J Biol Med. 2009;82(4):153-159.
De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695-747.
De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695-747.
Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24.
Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24.
von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007;6(12):967-974. doi:10.1038/nrd2400
von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007;6(12):967-974. doi:10.1038/nrd2400
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.